Being overweight or obese may hide true nutritional status of patients with cancer
the ONA take:
Most cancer treatments—surgery, chemotherapy, radiation, or chemoradiation—can result in significant nutrition-related side effects; therefore, all patients should be screened for nutritional status, even obese patients. The nutritional status of overweight or obese patients may be deceiving.
Obesity increases the risk for cancer, and many patients are overweight or obese at diagnosis. But they appear to be well-nourished so they are not screened. Researchers at the chemotherapy department at Larissa General Clinic in Thessaly, Greece, conducted a study of 1,469 patients with advanced cancer; 594 of them were overweight or obese. Using nutritional screenings and questionnaires, the researchers determined if overweight or obese patients were well nourished, at risk, or malnourished.
The patients were asked about weight loss, mobility, psychological stress, medical history, eating habits, and their view of their own nutritional status. Study results indicated that 12% of the overweight and obese cancer patients were, in fact, malnourished and more than half were at risk for being malnourished.
Whether patients with cancer benefit from maintaining a heavy body weight or achieving some limited degree of weight loss is unclear.
However, these researchers and others stress that obesity or overweight status in a patient with a cancer diagnosis should not preclude nutritional screening, which is usually done by a nurse, because nutritional status can have a huge impact on quality of life, treatment response, and overall patient outcomes.
All patients should be screened for nutritional status, even obese patients.
Obese cancer patients also tend to survive longer than underweight patients and that may further discourage nutritional screening, they add.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|